Drug intelligence / Profile preview

MOH-A2

Development stage: Preclinical
Lead developer: Multiomic Health
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MOH-A2 is a preclinical therapeutic candidate being developed by Multiomic Health for the treatment of chronic kidney disease (CKD), specifically targeting kidney inflammation and fibrosis across multiple etiologies. The drug was identified using Multiomic Health's proprietary precision medicine platform, which integrates multi-omics data from patient biobanks to identify specific disease endotypes and associated therapeutic targets. Multiomic Health is collaborating with Alloy Therapeutics to develop this asset, leveraging Alloy's ATX-Gx™ human antibody discovery platform. MOH-A2 is currently in the in vitro and in vivo validation stage of preclinical development, aimed at addressing the high unmet need in CKD patients who do not respond to current standard-of-care treatments.

Beyond the preview

Go deeper on MOH-A2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOH-A2.

Explore the full profile